Headlines about AC Immune (NASDAQ:ACIU) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AC Immune earned a news impact score of 0.12 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.8149843248124 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
ACIU traded up $0.21 during midday trading on Tuesday, hitting $9.01. 6,258 shares of the company were exchanged, compared to its average volume of 62,400. The company has a market capitalization of $512.76, a P/E ratio of -30.03 and a beta of 2.18. AC Immune has a 1-year low of $6.03 and a 1-year high of $13.91.
AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Tuesday, March 20th. The company reported $0.06 earnings per share for the quarter. The company had revenue of $16.64 million for the quarter. AC Immune had a negative return on equity of 22.12% and a negative net margin of 131.08%. analysts predict that AC Immune will post -1.06 earnings per share for the current fiscal year.
Several equities analysts recently issued reports on the company. Zacks Investment Research downgraded AC Immune from a “hold” rating to a “sell” rating in a research report on Thursday, April 5th. HC Wainwright assumed coverage on AC Immune in a research report on Thursday, April 5th. They issued a “buy” rating and a $18.00 target price on the stock. Credit Suisse Group downgraded AC Immune from an “outperform” rating to a “neutral” rating and cut their target price for the company from $18.00 to $14.00 in a research report on Friday, March 23rd. Finally, BidaskClub raised AC Immune from a “sell” rating to a “hold” rating in a research report on Friday, March 9th.
COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/17/ac-immune-aciu-earning-somewhat-favorable-media-coverage-study-shows.html.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as Alzheimer's (AD), Parkinson's, down syndrome, and glaucoma diseases.
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.